appropriately, but this business model increases the potential for intended or unintended overuse of subsequent interventions.
We stand by the statement Dr Lamb and colleagues take issue with: "establishing a discounted rate as a strategy to capture patients…creates a structure that can increase harms from excessive investigation of benign nodules." 2 The statement is not cited as evidence; it occurs in the discussion of issues regarding screening. We support mak ing screening accessible to those who need it but stand by the opinion that we need the health-care system to appropriately cover the costs of screening (not just the scan itself) with appropriate quality metrics. It would be a poor health policy decision to provide no other structure for lung cancer screening than an inherently confl icted business model with the assumption that it will always turn out to be managed well. We note that our view is consistent with federal policies enacted as part of the Health Insurance Portability and Accountability Act legislation ( § 1128A(a)(5) of the Social Security Act), which forbids gifting services to patients to garner their business.
In the absence of a health-care system structure, we support the efforts of institutions, including the laudable example of the Lahey Clinic, to fi nd a way to appropriately implement screening. We believe that clarity about actual costs and potential confl icts is useful in fi nding good ways to manage these issues. We have to be careful because it can be diffi cult to navigate the thin line between superfi cial statements and attractive sound bites that are motivated primarily by a personal agenda and arguments about how it is best for us to proceed with bringing a potential signifi cant health benefi t to those who need it.
Frank C. Detterbeck 
A Multidisciplinary Pulmonary Embolism Response Team
To the Editor:
In this report, we describe the successful introduction of a novel Pulmonary Embolism Response Team (PERT) to streamline the care of patients with severe pulmonary embolism (PE). The treatment of patients with massive and submassive PE remains controversial. 1 Different specialists bring different experience, technical expertise, and therapeutic recommendations. 1 , 2 To provide optimal care for complex patients with PE, a team approach is required. We formed the PERT with an infrastructure that would provide rapid, multidisciplinary consultation; mobilize resources; and facilitate research.
The PERT is composed of specialists in cardiology, emergency medicine, vascular medicine, cardiac surgery, and pulmonary/critical care with an interest in PE. We created an activation system consistent with published guidelines for rapid response teams. 3 , 4 An on-call PERT fellow responds to an activation and immediately convenes an online meeting of PERT members using commercially available software. This system enables team members to discuss the case while viewing data and radiologic images from any computer or mobile device via a password-protected login. In the fi rst 12 weeks, there were 30 unique PERT activations. Most (17, 57%) originated in the ED, seven (23%) in ICUs, and six (20%) in inpatient hospital units. Twenty-fi ve activations (83%) were for confi rmed PE and fi ve (17%) for unstable patients with suspected PE. Median elapsed time from the initial activation to the multidisciplinary online meeting was 54 min (25%-75%:
52-72 min). Data collection was approved by the Human Research Committee of Partners Healthcare (2012P002257).
The mean age of patients was 57 Ϯ 17 years, and 19 (63%) were men ( Table 1 ) . Seven of 25 confi rmed PEs (28%) were saddle and eight (32%) involved a main pulmonary artery. Twenty patients (80%) had right-sided heart strain. After consultation, the PERT considered 18 PEs (72%) submassive and two (8%) massive ( Fig 1 ) . Two patients (8%) were treated with thrombolysis (via catheter), 12 (40%) had a contraindication to thrombolysis, and fi ve (20%) had a vena cava fi lter placed. Three patients (12%) with confi rmed PE died.
To the authors' knowledge, the PERT at Massachusetts General Hospital is the fi rst such team in the country. Our initial experience suggests that an innovative, multidisciplinary PERT can streamline the care of patients with severe PE and that there is high demand for this approach. 
Speech and Mechanical Ventilation
We read with interest the recent CHEST article by Garguilo et al 1 (May 2013) about speech in patients with tracheostomy and mechanical ventilation (TMV) support being facilitated by simultaneously using two devices to permit essentially continuous speech. In 1990 , we reported on 104 users with TMV (82 of whom had neuromuscular diseases [NMDs] and were continuously TMV dependent) who spoke by using cuffless tubes or tubes with defl ated cuffs. 2 Nineteen had Duchenne muscular dystrophy. Most of them had the exhalation valves of their active ventilator circuits capped for continuous speech; this is a simpler and less expensive method for continuous speech during TMV, without requiring additional devices or causing dyspnea or hypercapnia from slight rebreathing. Indeed, most of the patients were chronically hypocapnic from long-term TMV. Passy-Muir valves also accomplish the same thing and are simpler and cheaper than the proposed positive end expiratory pressure (PEEP), 1 but neither these valves nor capping were discussed by Garguilo et al. 1 Thirty-four of the 104 users with TMV from our study were among the 69 decannulated to continuous noninvasive ventilatory support (CNVS) who preferred it to TMV for convenience, speech, swallowing, appearance, comfort, and safety unanimously overall; none underwent tracheotomy a second time. 3 After successfully extubating all "unweanable" patients with NMD other than those with amyotrophic lateral sclerosis, 4 we no longer consider tracheotomy for any NMDs other than amyotrophic lateral sclerosis. Over 760 further users on CNVS have been reported from 18 centers. 5 Thus, none of the 12 patients reported by Garguilo et al 1 would have undergone tracheotomy by our center, and all would have been able to speak well without PEEP. Indeed, only one-half of their 12 patients were continuously TMV dependent, despite having had tracheostomies for an average of . 13 years . Because long-term survival is possible by both TMV and CNVS (albeit at a mean 10 years longer for Duchenne muscular dystrophy with fewer hospitalizations and pneumonias by CNVS), TMV should
